Systematic Review
Accepted on 22 Jul 2024
Ramucirumab Plus FOLFIRI or Irinotecan as Second-Line Treatment for Patients with Gastroesophageal Adenocarcinoma: A Review and Meta-Analysis of an Emerging Option
in Gastrointestinal Cancers: Gastric and Esophageal Cancers